To determine the relative risk of developing atopic dermatitis in infants fed a study formula based on whole goat milk compared to infants a study formula based on cow milk protein.

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

Dairy Goat Co-operative

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe AD in Part 1 and to describe how similar is the current maintenance dosing regimen of lebrikizumab 250 mg every 4 weeks (Q4W) to the new proposed; lebrikizumab 500 mg every 12 weeks (Q12W), in terms of efficacy, safety, PK, ADA and blood biomarkers.

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Almirall

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis.

This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Mississauga, Canada

Auburn Hills, MI

Bay City, MI

Pharmacology Translational Unit

Jacksonville, FL

Tampa, FL

North Little Rock

Edmonton, AB

Calgary, Canada

San Antonio, Texas

Boise, ID

Monterrey, Mexico

Los Angeles, CA

Coorparoo, Australia

Cancer Centre for Children

Lilly

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Clinical Research Unit

Haematology Department

Kortrijk, Belgium

Maldegem, Belgium

Clinical Trial Center

Remscheid, Germany

Hannover, Germany

Leipzig, Germany

Szolnok, Hungary

Lublin, Poland

Tartu, Estonia

St. Johns, NL

Clinical Operations Department

Ottawa, Canada

Forest Hills Dermatology Group

Jose Garcia, Coordinator

New York, NY

Department of Cardiology

Ajax, Canada

Camp Hill, PA

Ontario, CA

Newmarket, Canada

Richmond Hill, Canada

Toronto, Canada

Richmond Hill, CA

Ontario, Canada

Towson, MD

Niagara Falls, Canada

Etobicoke, Canada

Oakvile, Canada

Burlington, Canada

Hamilton, Canada

Chevy Chase, MD

Waterloo, Canada

Internal Medicine Glennan Center for Geriatrics and Gerontology

San Juan, PR

Windsor, Canada

Derm Center

Troy, MI

Bexley, OH

Charlotte, NC

Indianapolis, IN

West Lafayette, Indiana

Boca Raton, FL

Miami Lakes, FL

Hialeah, FL

Coral Gables, FL

SLUCare Academic Pavilion - Endocrinology Division Research

Miami, FL

Cape Coral, FL

Saskatoon, Canada

Dermatology and Skin Cancer Center Leawood

Lincoln, NE

Vida Dermatology South

Edmonton, Canada

Hot Springs, AR

 Edmonton, Canada

Rapid City, SD

Tulsa, OK

Oklahoma City, OK

Plano, TX

Dallas, TX

Texas Medical Center

McGovern Medical School - ACTAT - Research Department

Bellaire, TX

Kelowna, Canada

San Antonio, TX

Albuquerque, NM

Portland, OR

Clinical Research Institute of Southern Oregon (CRISOR)

Scottsdale, AZ

Las Vegas, NV

Reno - Moana Lane Location

Research Center

Sacramento, CA

Dublin, CA

Bakersfield, CA

Northridge, CA

Long Beach, CA

Canoga Park, California

Santa Monica, CA

Buenos Aires, Argentina

Rosario, Argentina

Nagoya City University Hospital

Santiago, Chile

Carlton, Australia

Benowa, Australia

Amgen

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Find clinical trials for Eczema in Valencia, VC

Related conditions:

Eczema trials near Valencia, VC, ESP:

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope 2)

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Valencia, VC

Related conditions:

Eczema trials near Valencia, VC, ESP:

Goat Infant Formula Feeding and Eczema (the GIraFFE Study)

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope 2)

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Find clinical trials for Eczema in Valencia, VC